Arena launches Longboard Pharmaceuticals

By The Science Advisory Board staff writers

October 28, 2020 -- Arena Pharmaceuticals has launched Longboard Pharmaceuticals with $56 million in financing to support the development of the company's lead clinical and preclinical programs.

LP352 is a next-generation 5-HT2C agonist and a clinical stage program for treatment-resistant developmental and epileptic encephalopathies. Preclinical programs relating to LP143, a centrally acting, full agonist of the cannabinoid type 2 receptor, and LP659, a centrally acting, next-generation highly selective sphingosine 1-phosphate receptor modulator, are also being developed for the potential treatment of microglial neuroinflammatory diseases.

The new company will be focused on the development of novel central nervous system-targeted assets discovered by Arena's validated G protein-coupled receptor research engine.

Longboard, formerly known as Arena Neuroscience, was a wholly owned subsidiary of Arena Pharmaceuticals.

CNS Pharma partners with MD Anderson
Cancer biopharmaceutical company CNS Pharmaceuticals has entered into a sponsored research agreement with the University of Texas MD Anderson Cancer Center...
Inflammatory attack comes from an unexpected source in rheumatoid arthritis
Researchers have pinpointed immune cells called natural killer cells as an unexpected source of inflammatory proteins that contribute to rheumatoid arthritis....
Brain's immune system blocks blood immune cells from healing spinal injuries
Molecular and computational analysis of immune responses in the central nervous system reveals that the brain's immune system may prevent blood immune...

Copyright © 2020

International Society for Cell and Gene Therapy Annual Meeting
May 4 - June 7
San Francisco, California United States
Interphex 2022 Conference
May 24-26
New York, New York United States
American Society for Mass Spectrometry Annual Conference
June 5-9
Minneapolis, Minnesota United States
American Society for Microbiology Microbe Meeting
June 9-13
District of Columbia United States
HPLC 2022
June 18-23
San Diego, California United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter